Star Health: Reports Q2 FY27 Unaudited Results; Reclassifies Promoter Group Entity

Star Health and Allied Insurance Company Limited announced its un-audited financial results for the quarter and half-year ended September 30, 2026. The company reported its financial performance and also disclosed the reclassification of Sthitaprajna Advisors LLP from the Promoter Group Category to the Public Shareholder Category. The Board meeting concluded at 06:30 PM IST.

Financial Performance for Q2 FY27

Star Health and Allied Insurance Company Limited has released its un-audited financial results for the quarter and half-year period concluding on September 30, 2026. These results were considered and approved by the Board of Directors during their meeting held on October 27, 2026.

Key Financial Highlights

The disclosed financial results include the un-audited standalone financial statements for the quarter and half-year ended September 30, 2026, along with the Limited Review Report issued by the joint statutory auditors. Additionally, the company provided disclosures as required under Regulation 52(4) and a declaration regarding the utilization of issue proceeds of non-convertible securities as per Regulation 52(7)(A) of SEBI LODR.

Specific financial figures from the un-audited results for the quarter ended September 30, 2026, show a Net Profit/Loss of ₹26,481 lakhs from continuing operations. For the half-year ended September 30, 2026, the profit from continuing operations stood at ₹81,454 lakhs.

Promoter Group Reclassification

In a significant corporate announcement, the company’s Board also approved the reclassification of Sthitaprajna Advisors LLP. This entity will be moved from the Promoter Group Category to the Public Shareholder Category.

Board Meeting Details

The Board of Directors’ meeting commenced at 11:30 AM IST and concluded at 06:30 PM IST on October 27, 2026. The information regarding the financial results and the reclassification is also being hosted on the company’s website, www.starhealth.in, in compliance with SEBI LODR regulations.

Source: BSE

Previous Article

Piramal Pharma: Q2 FY27 Revenue Surges 28%, EBITDA Up 72%